Andrew C. Pearce

Andrew C. Pearce

Auto-generated profile, based on publicly available information

Andrew C. Pearce

Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, United Kingdom

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2021 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
DLDavid A Lomas
David A Lomas
JIJames Irving
James Irving
CAChristopher Arico‐Muendel
Christopher Arico‐Muendel
SBSvetlana Belyanskaya
Svetlana Belyanskaya
ABAndrew Brewster
Andrew Brewster
APAndrew C Pearce
Andrew C Pearce
Severe α 1 ‐antitrypsin deficiency results from the Z allele (Glu342Lys) that causes the accumulation of homopolymers of mutant α 1 ‐antitrypsin within the endoplasmic reticulum of hepatocytes in association with liver disease. We have used a DNA‐encoded chemical library to undertake a high‐throughput screen to identify small molecules that bind to, and stabilise Z α 1 ‐antitrypsin. The lead compound blocks Z α 1 ‐antitrypsin polymerisation in vitro , reduces intracellular polymerisation and increases the secretion of Z α 1 ‐antitrypsin threefold in an iPSC model of disease. Crystallographic and biophysical analyses demonstrate that GSK716 and related molecules bind to a cryptic binding pocket, negate the local effects of the Z mutation and stabilise the bound state against progression along the polymerisation pathway. Oral dosing of transgenic mice at 100 mg/kg three times a day for 20 days increased the secretion of Z α 1 ‐antitrypsin into the plasma by sevenfold. There was no observable clearance of hepatic inclusions with respect to controls over the same time period. This study provides proof of principle that “mutation ameliorating” small molecules can block the aberrant polymerisation that underlies Z α 1 ‐antitrypsin deficiency.

1 September 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JLJohn Liddle
John Liddle
VBVeronique Beneton
Veronique Beneton
MBMatthew Benson
Matthew Benson
RBRyan Bingham
Ryan Bingham
ABAnne Bouillot
Anne Bouillot
AHAlain HOVNANIAN
Alain HOVNANIAN

26 April 2019 in Acta Crystallographica Section F Structural Biology Communications
Verified
Journal Article
Closed access
PDF file
JTJames H. Thorpe
James H. Thorpe
EEEmma V. Edgar
Emma V. Edgar
KSKathrine J. Smith
Kathrine J. Smith
XLXiao Q. Lewell
Xiao Q. Lewell
MRMonika Rella
Monika Rella
AHAlain HOVNANIAN
Alain HOVNANIAN

28 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DLDavid A. Lomas
David A. Lomas
JIJames Irving
James Irving
CAChristopher Arico-Muendel
Christopher Arico-Muendel
SBSvetlana Belyanskaya
Svetlana Belyanskaya
ABAndrew Brewster
Andrew Brewster
APAndrew C. Pearce
Andrew C. Pearce
Severe α 1 -antitrypsin deficiency results from the Z allele (Glu342Lys) that causes the accumulation of homopolymers of mutant α 1 -antitrypsin within the endoplasmic reticulum of hepatocytes in association with liver disease. We have used a DNA-encoded chemical library to undertake a high throughput screen to identify small molecules that bind to, and stabilise Z α 1 -antitrypsin. The lead compound blocks Z α 1 -antitrypsin polymerisation in vitro , reduces intracellular polymerisation and increases the secretion of Z α 1 -antitrypsin three-fold in mammalian cells including an iPSC model of disease. Crystallographic and biophysical analyses demonstrate that GSK716 and related molecules bind to a cryptic binding pocket, negate the local effects of the Z mutation and stabilise the bound state against progression along the polymerization pathway. Oral dosing of transgenic mice at 100 mg/kg three times a day for 20 days increased the secretion of Z α 1 -antitrypsin into the plasma by 7-fold. There was no observable clearance of hepatic inclusions with respect to controls. This study provides proof-of-principle that ‘mutation ameliorating’ small molecules are a viable approach to treat protein conformational diseases.